FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2330778866> ?p ?o ?g. }

• W2330778866 abstract "Introduction Background Mucosal healing (MH) is an increasingly important therapeutic goal in inflammatory bowel disease. Monoclonal antibody (MA) therapy aims to achieve this and faecal calprotectin (FC) concentration has been shown as a surrogate marker for MH. Aims Our aim was to study the profile of Crohn’s disease (CD) patients on MA therapy and evaluate whether FC levels after induction therapy with MA predicts the medium-term outcome. Methods Thirty-two CD patients: infliximab n = 11, adalimumab n = 21 were identified from our MA database. Data on demography and disease characteristics were extracted from case records. A subset of CD patients with FC levels measured both at baseline and after induction therapy were analysed further for response to therapy and disease course during follow-up (n = 10). Disease activity was evaluated by modified Harvey-Bradshaw index at baseline, after induction, and at 6 and 12 months during maintenance therapy. Results Of 32 patients, 22 patients were female, medium age 39.5 (range: 19–65 year), medium age at diagnosis 30.2 (range: 16–61year), mean disease duration prior to MA was 6.1 (range: 10 –22 year) and 21.8% has family history of inflammatory bowel disease. Of these, 56.2% had history of surgery prior to MA and 71.7% had concurrent immunomodulation. Disease phenotypes are shown in table. Of the 10 patients with full FC data, 6 patients normalised FC after induction (median levels 67 mg/kg, median 64 mg/ks, range 30–72). All remained in remission during follow-up median- 22 months (range 13–33 months). Four patients failed to normalise FC levels with induction therapy (median 11 months, range 6–39). Of these, 2 had operation, 2 had multiple relapses (1 treated with prolonged enteral therapy and 1 with additional oral corticosteroid courses). Conclusion MA therapy is used in CD patients with aggressive disease course who are treated/intolerant to immunomodulatory therapy. Normalisation of FC after induction therapy with MA is a useful marker to predict sustained clinical remission. Disclosure of Interest None Declared." @default.
• W2330778866 created "2016-06-24" @default.
• W2330778866 creator A5004828985 @default.
• W2330778866 creator A5015479415 @default.
• W2330778866 creator A5033995791 @default.
• W2330778866 creator A5089651452 @default.
• W2330778866 creator A5090612579 @default.
• W2330778866 date "2013-06-01" @default.
• W2330778866 modified "2023-09-22" @default.
• W2330778866 title "PTH-085 Monoclonal Antibody Therapy in Crohn’S Disease: Does Serial Faecal Calprotectin Play a Role?: Abstract PTH-085 Table 1" @default.
• W2330778866 doi "https://doi.org/10.1136/gutjnl-2013-304907.572" @default.
• W2330778866 hasPublicationYear "2013" @default.
• W2330778866 type Work @default.
• W2330778866 sameAs 2330778866 @default.
• W2330778866 citedByCount "0" @default.
• W2330778866 crossrefType "journal-article" @default.
• W2330778866 hasAuthorship W2330778866A5004828985 @default.
• W2330778866 hasAuthorship W2330778866A5015479415 @default.
• W2330778866 hasAuthorship W2330778866A5033995791 @default.
• W2330778866 hasAuthorship W2330778866A5089651452 @default.
• W2330778866 hasAuthorship W2330778866A5090612579 @default.
• W2330778866 hasBestOaLocation W23307788661 @default.
• W2330778866 hasConcept C126322002 @default.
• W2330778866 hasConcept C159654299 @default.
• W2330778866 hasConcept C163864487 @default.
• W2330778866 hasConcept C203014093 @default.
• W2330778866 hasConcept C2777138892 @default.
• W2330778866 hasConcept C2777843201 @default.
• W2330778866 hasConcept C2778260677 @default.
• W2330778866 hasConcept C2778292693 @default.
• W2330778866 hasConcept C2779008522 @default.
• W2330778866 hasConcept C2779134260 @default.
• W2330778866 hasConcept C2779280984 @default.
• W2330778866 hasConcept C2780132546 @default.
• W2330778866 hasConcept C542903549 @default.
• W2330778866 hasConcept C71924100 @default.
• W2330778866 hasConcept C90924648 @default.
• W2330778866 hasConceptScore W2330778866C126322002 @default.
• W2330778866 hasConceptScore W2330778866C159654299 @default.
• W2330778866 hasConceptScore W2330778866C163864487 @default.
• W2330778866 hasConceptScore W2330778866C203014093 @default.
• W2330778866 hasConceptScore W2330778866C2777138892 @default.
• W2330778866 hasConceptScore W2330778866C2777843201 @default.
• W2330778866 hasConceptScore W2330778866C2778260677 @default.
• W2330778866 hasConceptScore W2330778866C2778292693 @default.
• W2330778866 hasConceptScore W2330778866C2779008522 @default.
• W2330778866 hasConceptScore W2330778866C2779134260 @default.
• W2330778866 hasConceptScore W2330778866C2779280984 @default.
• W2330778866 hasConceptScore W2330778866C2780132546 @default.
• W2330778866 hasConceptScore W2330778866C542903549 @default.
• W2330778866 hasConceptScore W2330778866C71924100 @default.
• W2330778866 hasConceptScore W2330778866C90924648 @default.
• W2330778866 hasLocation W23307788661 @default.
• W2330778866 hasOpenAccess W2330778866 @default.
• W2330778866 hasPrimaryLocation W23307788661 @default.
• W2330778866 isParatext "false" @default.
• W2330778866 isRetracted "false" @default.
• W2330778866 magId "2330778866" @default.
• W2330778866 workType "article" @default.